Home - Aprea
Description: Aprea Therapeutics focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways.
dna damage response (ddr) inhibitors; precision oncology; geneti (1)
Aprea’s precision oncology pioneers develop highly selective, potentially less toxic DDR-targeted therapeutics that are designed to address a significant unmet medical need for cancer patients with mutations in DNA damage response (DDR) genes.
Our diversified portfolio of clinical and pre-clinical assets presents a pioneering new approach that maximizes efficacy by improving tolerability.
See what makes us different
Home - Aprea